Sunday, June 13, 2021 | Dhu al-Qaadah 2, 1442 H
clear sky
weather
OMAN
32°C / 32°C
EDITOR IN CHIEF- ABDULLAH BIN SALIM AL SHUEILI

Merck to buy Antelliq for $2.4 bn

1076735
1076735


NEW JERSEY: Merck and Co said it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros ($2.37 billion) to bolster its fast-growing animal health business.


The move affirms the drugmaker’s commitment to the business, which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co and Pfizer Inc did.


Pfizer’s Zoetis raised $2.2 billion in a 2013 IPO, while Elanco, the former animal health business at Lilly, raised $1.51 billion from an IPO in September.


Merck’s Chief Executive Officer Kenneth Frazier had said in October that the company was a “good owner” of its animal health unit.


“We believe that we run this business very well inside the company compared to our competitors,” he had said.


Merck’s unit has been a big player in the animal health segment, bringing in sales of $3.88 billion in 2017. Zoetis recorded $5.31 billion in revenue, while Elanco brought Lilly $3.09 billion in sales the same year.


Merck said Antelliq will be a wholly owned and separately operated subsidiary within its animal health division.


Antelliq’s products, which brought in 360 million euros ($406.51 million) in sales in the year ended September 30, provide veterinarians, farmers and pet owners with digital technology that monitors animals and predicts disease in them.


These products allow access to real-time, actionable information to help improve livestock management and health outcomes, Merck said in a statement. — Reuters



SHARE ARTICLE
Most Read
No Image
Oman announces vaccination plans for June, July Digital vaccine passport, next travel document The Chedi Muscat makes official statement Riyada clarifies on expatriate permit fees
FOLLOW US
arrow up
home icon